原文转载自生物谷，已获转载授权
最近来自法国的科学家们开发了一种超声装置并且对15名出现复发的成胶质细胞瘤病人进行了实验装置检测，科学家开发这种装置的目的在于突破血脑屏障帮助化疗药物到达脑部。相关研究结果发表在国际学术期刊Science Translational Medicine上。
研究人员解释了这种超声装置的工作原理：将装置植入病人头骨，位于肿瘤区域上面，装置开启之后超声波会引起微泡振动短暂打开血脑屏障，这样就能够帮助化疗药物到达肿瘤部位。每次化疗之前都需要开启超声装置，低强度超声两分钟时间就足以打开血脑屏障持续大约六个小时，这样可以将药物浓度增加五到七倍。
在这项研究中，研究人员使用了化疗药物carboplatin进行检测，每个月对病人进行一次实验性治疗，最多进行六个月，治疗期间进行肿瘤进展情况的检测。
据研究人员所说，这种超声装置对于大脑负责语言，行动和其他感官的区域都比较安全。1期临床研究的目的并不是检测通过血脑屏障的化疗药物剂量更高是否会更加有效，但是研究结果表明所有参与研究的病人中有9人的肿瘤生长没有进一步发展。
血脑屏障是由细胞紧密排列形成的将脑部与外部环境隔绝开来的保护性屏障，血脑屏障在阻止有害化学物质及细菌进入大脑的同时也将大部分口服和静脉注射药物阻挡在外。这项研究开发的超声装置为解决化疗药物到达脑部肿瘤位置，增加化疗药物浓度的问题提供了有效的解决办法，对于脑部肿瘤的治疗具有非常重要的应用价值。（生物谷Bioon.com）
DOI: 10.1126/scitranslmed.aaf6086
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Alexandre Carpentier1,2,*, Michael Canney3, Alexandre Vignot3, Vincent Reina1,2, Kevin Beccaria1, Catherine Horodyckid1, Carine Karachi1,2, Delphine Leclercq4, Cyril Lafon5, Jean-Yves Chapelon5, Laurent Capelle1, Philippe Cornu1,2, Marc Sanson2,6,7,8,9, Khê Hoang-Xuan2,6,7,8,9, Jean-Yves Delattre2,6,7,8,9 and Ahmed Idbaih
The blood-brain barrier (BBB) limits the delivery of systemically administered drugs to the brain. Methods to circumvent the BBB have been developed, but none are used in standard clinical practice. The lack of adoption of existing methods is due to procedural invasiveness, serious adverse effects, and the complications associated with performing such techniques coincident with repeated drug administration, which is customary in chemotherapeutic protocols. Pulsed ultrasound, a method for disrupting the BBB, was shown to effectively increase drug concentrations and to slow tumor growth in preclinical studies. We now report the interim results of an ultrasound dose-escalating phase 1/2a clinical trial using an implantable ultrasound device system, SonoCloud, before treatment with carboplatin in patients with recurrent glioblastoma (GBM). The BBB of each patient was disrupted monthly using pulsed ultrasound in combination with systemically injected microbubbles. Contrast-enhanced magnetic resonance imaging (MRI) indicated that the BBB was disrupted at acoustic pressure levels up to 1.1 megapascals without detectable adverse effects on radiologic (MRI) or clinical examination. Our preliminary findings indicate that repeated opening of the BBB using our pulsed ultrasound system, in combination with systemic microbubble injection, is safe and well tolerated in patients with recurrent GBM and has the potential to optimize chemotherapy delivery in the brain.
文章转载自生物谷，以下为授权信息：
与癌争锋：一群肿瘤专科医师的理想集散地；
邮箱：yuaizf@126.com，如果您有任何好的文章或者建议，请联系我们。
评论